Impact of T2R38 Receptor Polymorphisms on Pseudomonas aeruginosa Infection in Cystic Fibrosis
To the Editor:
The T2R38 (taste receptor 2 member 38) bitter taste receptor on respiratory epithelia detects Pseudomonas aeruginosa N-acyl-Lhomoserine lactones (AHLs). In vitro, T2R38 activation by AHLs initiates calcium-mediated increases in nitric oxide production and ciliary beat frequency, dependent on polymorphisms in the TAS2R38 gene (1) . In patients with chronic rhinosinusitis, the TAS2R38 genotype is proposed to modify mucosal responses to P. aeruginosa (1) .
Polymorphisms in the TAS2R38 gene result in two high-frequency haplotypes associated with taste perception of the bitter compound phenylthiocarbamide (2) . The "taster" haplotype codes proline-alanine-valine (PAV), and the "nontaster" haplotype codes alanine-valine-isoleucine (AVI) at positions 49, 262, and 296 in the receptor protein. Responses to AHLs in vitro are greatest in PAV/PAV epithelial cells, and this genotype is reported to be protective against P. aeruginosa in the sinonasal airway (1) .
P. aeruginosa is the most frequently isolated respiratory pathogen in cystic fibrosis (CF), and chronic infection is associated with accelerated rates of disease progression. Determining the impact of TAS2R38 polymorphisms on P. aeruginosa infection in CF could have implications for patient risk stratification and, as naturally occurring and synthetic agonists to T2R38 are already in clinical use (3), could identify promising therapeutic targets.
We characterized T2R38 localization in the CF airway and investigated the hypothesis that TAS2R38 polymorphisms would modify the prevalence and impact of P. aeruginosa infection in CF. Some of the results of these studies have previously been reported in the form of abstracts (4, 5) .
Methods
Nasal and/or bronchial brushings were obtained from four children with CF undergoing bronchoscopy and four healthy adult controls. T2R38 localization was evaluated by immunocytochemistry with antibodies to T2R38 and ciliary proteins as described previously (6) . Slides were imaged with a Zeiss LSM-510 confocal microscope, and colocalization was quantified using the JACoP plug-in for ImageJ (7) .
DNA was extracted from blood from 271 subjects with CF (.6 yr old) and subjected to PCR for the common TAS2R38 polymorphisms rs713598, rs1726866, and rs10246939. P. aeruginosa infection status was categorized in patients with three or more respiratory cultures during 2014, according to Leeds criteria (8) , as chronic (.50% positive), intermittent (<50% positive), free (previous P. aeruginosa but none for .12 mo), or never. Clinical data were obtained from each patient's 2014 annual assessment.
Cryopreserved P. aeruginosa isolates from TAS2R38-genotyped patients (matched for age and FEV 1 ) were revived in Luria-Bertani broth in triplicate and filter sterilized. Quantitative analysis of N-butanoyl-L-homoserine lactone (C4-HSL) and N-(3-oxododecanoyl)-L-homoserine lactone (3-oxo-C12-HSL) was performed by liquid chromatography with tandem mass spectrometry. The limits of detection and limits of quantification were defined as signal:noise ratios of 3:1 and 10:1, respectively, as previously described (9) .
Power calculations predicted that 250 patients would provide 80% power to detect a difference in chronic P. aeruginosa infection of >20% in PAV/PAV compared with other genotypes at an a of 5%. P. aeruginosa infection by TAS2R38 genotype was analyzed by chi-squared analysis and logistic regression. Graphpad Prism 7 and SPSS 23 were used, and the null hypothesis was rejected at P , 0.05.
Ethics review committees approved the protocol (02-019 and 10/H0504/9), and written consent was obtained from the subjects or their parent/guardian.
Results
T2R38 immunostaining was present in all nasal (n = 3) and bronchial (n = 3) samples from patients with CF, and in all nasal samples (n = 4) from healthy controls. T2R38 stained proximally to acetylated a-tubulin (ciliary microtubules) and g-tubulin (ciliary basal bodies), and colocalized with rootletin (ciliary rootlets) in CF and control cells (Figure 1) . The thresholded Manders' correlation coefficients (mean 6 SD of four cells) for T2R38 and rootletin were 0.91 6 0.07, 0.90 6 0.08, and 0.90 6 0.04 for control nasal, CF nasal, and CF bronchial cells, respectively, indicating that >90% of green (rootletin) pixels were positive for red (T2R38).
Of 271 patients with CF, 225 had the common AVI/AVI (n = 74), AVI/PAV (n = 110), or PAV/PAV (n = 41) genotypes and three or more respiratory cultures during 2014. Between TAS2R38 genotype groups there was no significant difference in median age, sex, or proportion of p.Phe508del CFTR (cystic fibrosis transmembrane conductance regulator) mutations. There was no association between TAS2R38 genotype and P. aeruginosa infection status (P = 0.46; Table 1 ). In the logistic regression model with "intermittent and chronic" and "never and free" groups as dependent variables, and age, sex, CFTR genotype, and TAS2R38 genotype as independent variables, only age was associated with intermittent or chronic P. aeruginosa infection (odds ratio, 1.05; 95% confidence interval, 1.03-1.07). There was no association between TAS2R38 genotype and P. aeruginosa infection status when the PAV/PAV genotype was compared against the AVI/AVI or AVI/PAV genotype. Among patients with intermittent or chronic P. aeruginosa infection (n = 141), there was no difference by TAS2R38 genotype in median FEV 1 % predicted (AVI/AVI, 54.0%; AVI/PAV, 62.0%; PAV/PAV, 53.5%; P = 0.3) or in the proportion of patients from whom mucoid P. aeruginosa was isolated (AVI/AVI, 69%; AVI/PAV, 60%; PAV/PAV, 68%; P = 0.5). In 18 P. aeruginosa isolates from TAS2R38-genotyped patients, there was no difference by genotype in the proportion of isolates in which C4-HSL or 3-oxo-C12-HSL was below the limit of quantification (P = 0.8).
Discussion
We have identified T2R38 in CF nasal and bronchial epithelium, where it localizes to the ciliary rootlet with the same distribution as in non-CF epithelia. Previous studies reported T2R38 localization ranging from the ciliary tip (10) to below the ciliary base (1, 11) . Our experiments demonstrate that in fresh, noncultured cells, T2R38 colocalizes with rootletin, a structural component of the ciliary rootlet, originating from the ciliary basal body and extending toward the nucleus (12) .
In this study of 225 children and adults with CF, we found no association between the TAS2R38 genotype and P. aeruginosa infection status within the range of differences that our study was powered to detect. Our results show that only age was associated with intermittent or chronic infection, consistent with CF registry data (13) . Among patients with intermittent or chronic infection, the lack of any difference in spirometry or prevalence of mucoid P. aeruginosa further supports the lack of a protective effect of the PAV/PAV genotype. Finally, in a small sample of clinical isolates, we observed no relationship between the TAS2R38 genotype and AHL profiles, suggesting that polymorphisms in this receptor do not exert a selective pressure on P. aeruginosa in the CF lung.
Our results indicate that TAS2R38-related differences in sinonasal immunity do not translate to clinically relevant changes in the CF airway, where mucociliary clearance is significantly impaired. We suggest that TAS2R38 genotyping has no prognostic value in patients with CF, nor do our findings indicate that the T2R38 receptor is a promising drug target for CF mucosal immunity. n 
H2 Receptor Antagonist Use and Mortality in Pulmonary Hypertension: Insight from the VA-CART Program
Pulmonary hypertension (PH) is common and predicts or mediates poor outcomes in many medical disorders (1) . Independent of the underlying etiology, persons affected by PH have increased right-ventricular load and often develop right-heart failure. Pulmonary vasodilators are beneficial in some forms of PH (e.g., pulmonary arterial hypertension), but they can be harmful or have no impact in other forms (2) . Histamine H2 receptor antagonism may be relevant in the myocardial stress response and beneficial in right-heart dysfunction and right-heart failure (3-6). To explore this possibility, we examined relationships between H2 receptor antagonist (H2RA) use and mortality in a cohort of veterans with PH confirmed at right-heart catheterization (RHC).
Methods
We included veterans from the Veterans Affairs (VA) Clinical Assessment, Reporting, and Tracking (VA-CART) program who received RHC at a VA center between 2008 and 2014, had a mean pulmonary artery pressure (mPAP) of >25 mm Hg, and had a pulmonary artery wedge pressure (PAWP) recorded. The Colorado Multiple Institutional Review Board approved this study (#14-1649) .
Exposure. Participants were considered to have used an H2RA if an outpatient prescription was filled within 90 days of the RHC. Participants were excluded if they died within 90 days or had a hospitalization lasting longer than 60 days after catheterization. This provided at least 30 days to detect outpatient medication use.
Outcome. The outcome was the rate of all-cause mortality determined using the combined VA vital status file (97.6% exact agreement with the National Death Index) (7) . Risk time accrued after the 90-day window that was used to establish exposure status. Exposure and outcome assessment did not temporally overlap in an effort to avoid immortal time bias.
Statistical Analysis
We used Cox proportional hazards models to estimate associations between H2RA use and mortality. In limited models, we adjusted for age, sex, race, and body mass index. In fully adjusted models, we also accounted for participants' markers of socioeconomic status and health behaviors. In separate models, we further adjusted for comorbid medical conditions or comedication use.
To account for confounding by indication, analyses were repeated in a restricted cohort comparing participants who used H2RAs with those who used proton pump inhibitors. In a second restricted cohort, propensity scores were used to match H2RA users with nonusers. Analyses were repeated in cohorts limited to participants with a diagnosis of heart failure or chronic obstructive pulmonary disease (COPD).
Careful phenotyping by World Health Organization group was not feasible; however, PAWP was available for all participants. PAWP was evaluated as an effect modifier of the relationship between H2RA use and mortality. A typical cutoff of 15 mm Hg and a more stringent cutoff of 12 mm Hg to exclude left-heart disease were used.
Analyses were performed using SAS 9.4 (SAS Institute) and R 3.3.1 (R Project for Statistical Computing).
Results
Participant characteristics are included in Table 1 . A total of 589 H2RA users died in 4,719 person-years (12.5 deaths per 100 person-years) and 6,341 nonusers died in 46,129 person-years (13.7 deaths per 100 person-years). H2RA use within 90 days of RHC was associated with a 10% lower risk for all-cause mortality (adjusted hazard ratio, 0.90; 95% confidence interval, 0.83-0.98; P = 0.02; the proportional hazard assumption was not violated). This relationship was slightly stronger when we accounted for comedication use, accounted for comorbidity, compared H2RA users with users of proton pump inhibitors, and when we compared H2RA users with propensity-matched nonusers (Table 2) . When associations were evaluated in cohorts limited to veterans with COPD or heart failure, estimates were similar to those obtained in the full cohort but less precise.
There was no evidence that PAWP modified relationships between H2RAs and mortality using either conventional (15 mm Hg; 
